Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 33.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 194,088 shares of the medical equipment provider’s stock after selling 99,302 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.09% of Hologic worth $13,992,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cerity Partners LLC raised its stake in Hologic by 50.6% in the third quarter. Cerity Partners LLC now owns 59,884 shares of the medical equipment provider’s stock valued at $4,878,000 after buying an additional 20,132 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Hologic by 29.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 183 shares during the last quarter. Private Trust Co. NA boosted its stake in Hologic by 19.6% in the 3rd quarter. Private Trust Co. NA now owns 1,166 shares of the medical equipment provider’s stock worth $95,000 after purchasing an additional 191 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Hologic by 3.9% during the third quarter. Bank of Montreal Can now owns 492,210 shares of the medical equipment provider’s stock valued at $39,780,000 after buying an additional 18,532 shares during the last quarter. Finally, Dai ichi Life Insurance Company Ltd purchased a new stake in Hologic during the 3rd quarter valued at about $757,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of several research reports. Citigroup decreased their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Price Performance

NASDAQ:HOLX opened at $61.32 on Friday. The stock has a 50 day moving average of $65.24 and a two-hundred day moving average of $73.35. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The firm has a market cap of $13.76 billion, a P/E ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.